tolvaptan

You have accessRestricted Access
Long-Term Safety of Tolvaptan in ADPKD
Dipal M. Patel and Neera K. Dahl

CJASN January 2021, 16 (1) 3-5; DOI: https://doi.org/10.2215/CJN.17981120

Add to Selected Citations
Open Access
Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst, Ron T. Gansevoort, Ronald D. Perrone, Jennifer Lee, Molly E. Hoke, Alvin Estilo and Olga Sergeyeva

CJASN January 2021, 16 (1) 48-58; DOI: https://doi.org/10.2215/CJN.10250620

Add to Selected Citations
You have accessRestricted Access
Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan
Matteo Bargagli, Nasser A. Dhayat, Manuel Anderegg, Mariam Semmo, Uyen Huynh-Do, Bruno Vogt, Pietro Manuel Ferraro and Daniel G. Fuster

CJASN July 2020, 15 (7) 1007-1014; DOI: https://doi.org/10.2215/CJN.13861119

Add to Selected Citations
You have accessRestricted Access
ADPKD, Tolvaptan, and Nephrolithiasis Risk
Ewout J. Hoorn and Robert Zietse

CJASN July 2020, 15 (7) 923-925; DOI: https://doi.org/10.2215/CJN.07610520

Add to Selected Citations
You have accessRestricted Access
A Post Hoc Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials
Susan E. Shoaf, John Ouyang, Olga Sergeyeva, Alvin Estilo, Hui Li and Deborah Leung

CJASN May 2020, 15 (5) 643-650; DOI: https://doi.org/10.2215/CJN.08170719

Add to Selected Citations
You have accessRestricted Access
Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease
Kristen L. Nowak and Katharina Hopp

CJASN April 2020, 15 (4) 577-584; DOI: https://doi.org/10.2215/CJN.13291019

Add to Selected Citations
You have accessRestricted Access
Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
Marie E. Edwards, Fouad T. Chebib, Maria V. Irazabal, Troy G. Ofstie, Lisa A. Bungum, Andrew J. Metzger, Sarah R. Senum, Marie C. Hogan, Ziad M. El-Zoghby, Timothy L. Kline, Peter C. Harris, Frank S. Czerwiec and Vicente E. Torres

CJASN August 2018, 13 (8) 1153-1161; DOI: https://doi.org/10.2215/CJN.01520218

Add to Selected Citations
Open Access
Burden of Proof for Tolvaptan in ADPKD
Reem A. Mustafa and Alan S.L. Yu

CJASN July 2018, 13 (7) 1107-1109; DOI: https://doi.org/10.2215/CJN.00190118

Add to Selected Citations
You have accessRestricted Access
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial
Vicente E. Torres, Eiji Higashihara, Olivier Devuyst, Arlene B. Chapman, Ronald T. Gansevoort, Jared J. Grantham, Ronald D. Perrone, John Ouyang, Jaime D. Blais and Frank S. Czerwiec

CJASN May 2016, 11 (5) 803-811; DOI: https://doi.org/10.2215/CJN.06300615

Add to Selected Citations
You have accessRestricted Access
Mild Chronic Hyponatremia in the Ambulatory Setting: Significance and Management
Helbert Rondon-Berrios and Tomas Berl

CJASN December 2015, 10 (12) 2268-2278; DOI: https://doi.org/10.2215/CJN.00170115

Add to Selected Citations

Main menu

User menu

Search

tolvaptan

Articles

Information for Authors

About

Journal Information

More Information